Market Overview:
Global Influenza Diagnostics Market Size Was Valued at USD 1.11 Billion in 2022, and is Projected to Reach USD 1.47 Billion by 2030, Growing at a CAGR of 3.6% From 2023-2030.
Influenza, also referred to as the flu, is a virus-based respiratory condition. Coughing or sneezing is typically how the flu virus is spread from one person to another. Additionally, if you touch your nose or eyes after contacting a surface that has the flu virus on it, you could contract the illness. Seasonal flu occurs when the flu is most prevalent across particular seasons of the year. Furthermore, the flu season in the US might start in October and last until May. Millions of Americans contract the flu virus each flu season. Muscle aches, fever, and other unpleasant symptoms are some of the typical flu symptoms people experience, but they pass in a week.
Top Key Players for Influenza Diagnostics Market:
- Danaher Corporation (US)
- Siemens Healthineers (Germany)
- Thermo Fisher Scientific Inc. (US)
- Abbott Laboratories Inc. (Us)
- Hologic Inc. (US)
- bioMérieux SA (France)
- Quidel Corporation (US)
- Dickinson and Company (US)
- Meridian Bioscience (US)
- GenMark Diagnostics Inc. (US)
- Luminex Corporation (US)
- Tecan Trading AG (Switzerland)
- DiaSorin SA (Italy)
- altona Diagnostics GmbH (Germany)
- SEKISUI Diagnostics (US)
- SA Scientific Ltd. (US)
- Mast Group Ltd. (UK)
- Genome Diagnostics Pvt. Ltd. (India)
- Germaine Laboratories Inc. (US)
- Response Biomedical Corp. (Canada)
- Tauns LaboratoriesInc. (Japan), and Other Major Players
Market Dynamics and Factors:
The need for precise influenza virus detection has been sparked by the rise in influenza outbreaks in recent years. Additionally, influenza diagnostic tests assist in verifying or ruling out the existence of the virus in individuals who are exhibiting symptoms, propelling the growth of the influenza diagnostic market throughout the course of the forecast period. According to a WHO report from 2019, influenza was the major cause of serious illness or death in people at high risk, such as the elderly, children, and pregnant women.
The increase in influenza incidence and the growing demand for early influenza virus identification are giving market players crucial chances to provide diagnostic tests that are quick and can deliver reliable results. Additionally, to lessen the financial burden brought on by the prevalent virus, governments around the world are funding research and development of influenza diagnostic tests. In addition, the Human Genome Project's scientific developments in genomics and proteomics have led to the creation of cutting-edge diagnosis methods that can be used to treat influenza infections.
The Report Will Include A Major Chapter
- Patent Analysis
- Regulatory Framework
- Technology Roadmap
- BCG Matrix
- Heat Map Analysis
- Price Trend Analysis
- Investment Analysis
Key Industry Development:
- In June 2023, BD (Becton, Dickinson and Company), a leading global medical technology company, held a grand opening ceremony for its new €4 million research and development facility in Blackrock, Dublin. Additionally, the company announced an additional €30 million investment to expand its manufacturing facility in Enniscorthy, Wexford.
- In March 2023, Danaher Corporation, a global science and technology innovator, announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation. The partnership, which spanned multiple years, aimed to develop new technologies that would enhance the consistency of clinical outcomes for patients and address manufacturing bottlenecks in the delivery of next-generation engineered cell products.
Influenza Diagnostics Market Report Highlight:
- By Type, the Influenza Diagnostic Market is segmented into traditional and molecular tests. The Rapid Influenza Detection Tests (RIDTs) a type of traditional test segment is forecasted to dominate the Influenza Diagnostic Market. The key factor boosting the development of this market is the capacity to identify influenza viruses within 15 minutes with low to moderate sensitivity and high specificity.
- By End Users, the diagnostic laboratories segment is expected to lead the Influenza Diagnostic Market throughout the forecast. The key factor driving the growth of this market is the expansion in diagnostic laboratories and the outsourcing of diagnostic testing services by hospitals to large commercial diagnostic laboratories.
- The North American region is expected to have the highest share of the Influenza Diagnostics market over the projected period. The main factor promoting the growth of the influenza diagnostic market in this region is the existence of top leading companies engaged in the production of influenza diagnostic products and the significant expenditures made by governments on the development of novel fast diagnosing techniques to detect influenzas.
Central to our report are the company profiles and competitive analysis, providing insights into market players' overview, market role, and operating business segments. We evaluate their financial performance, production volume, sales volume, and sales margin, while highlighting recent market developments. Our market research offers invaluable intelligence and strategic insights to drive informed decision-making. By capitalizing on emerging opportunities and understanding the competitive landscape, our report empowers businesses to thrive in the Global Influenza Diagnostics Market.
Influenza Diagnostics Market Segmentation:
By Type
- Traditional
- Rapid Influenza Detection Tests
- Viral Culture
- Immunoassay Kits
- Others
- Molecular
- Rapid Molecular Assays
- Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
- Nucleic Acid Amplification
By End Users
- Clinical Laboratories
- Hospitals
- Research & Academic Institutes
- Diagnostic Laboratories
For this report, Introspective Market Research has segmented the Influenza Diagnostics Market based on region:
Regional Outlook (Revenue in USD Million; Volume in Units, 2023-2030)
North America
- The U.S.
- Canada
- Mexico
Eastern Europe
- Russia
- Bulgaria
- The Czech Republic
- Hungary
- Poland
- Romania
- Rest of Eastern Europe
Western Europe
- Germany
- UK
- France
- Netherlands
- Italy
- Spain
- Rest of Western Europe
Asia Pacific
- China
- India
- Japan
- Singapore
- Australia
- New-Zealand
- Rest of APAC
Middle East & Africa
- Turkey
- Saudi Arabia
- Qatar
- UAE
- Israel
- South Africa
South America
- Brazil
- Argentina
- Rest of SA
